Document 0874
 DOCN  M95A0874
 TI    The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief
       assessment of patients' subjective response to treatment for
       anorexia/cachexia.
 DT    9510
 AU    Cella DF; VonRoenn J; Lloyd S; Browder HP; Division of Psychosocial
       Oncology, Rush Cancer Institute,; Chicago, IL 60612, USA.
 SO    Qual Life Res. 1995 Jun;4(3):221-31. Unique Identifier : AIDSLINE
       MED/95338196
 AB    A brief visual analogue instrument was developed and tested in the
       context of a multicentre randomized double-blinded four-dose trial of
       megestrol acetate for the treatment of AIDS-related anorexia/cachexia.
       This nine-item instrument, the Bristol-Myers Anorexia/Cachexia Recovery
       Instrument (BACRI), was administered every 4 weeks after initiation of
       study drug (placebo vs 100 mg, 400 mg or 800 mg of drug). The purpose of
       the instrument was to quantify patient perception of benefit in areas
       such as decreased concern over weight, decreased concern over
       appearance, increased pleasure in eating and increase in global
       perception of quality of life. Post-trial psychometric evaluation of the
       instrument strongly supported the use of a seven-item index of
       subjective recovery from symptoms of anorexia/cachexia (BACRI-7) and a
       single criterion item depicting patient perception of benefit (BACRI-1).
       The BACRI-7 and BACRI-1 scales showed significant improvement over 12
       weeks in patients who received higher dose active drug (400 and 800 mg)
       compared with the placebo and 100 mg doses. Further differentiation of
       400 vs 800 mg arms was seen in the BACRI-7 results, consistent with
       dose-response improvements in weight and lean body mass changes.
       Quadratic trends over time in lean body mass change and provider-rated
       appetite grade suggested peak therapeutic effect at 8 weeks for these
       endpoints, whereas the absence of these trends in overall weight and
       patient-reported BACRI scores suggested that these benefits are more
       persistent. Although subjective (patient-reported) benefit is strongly
       associated with objective indicators of improvement, there remains the
       possibility that there is some added, independent benefit of megestrol
       acetate to subjective well-being.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult  Aged
       Anorexia/*DRUG THERAPY  Appetite/DRUG EFFECTS  Body Weight/DRUG EFFECTS
       Cachexia/*DRUG THERAPY  Dose-Response Relationship, Drug  Double-Blind
       Method  Human  Karnofsky Performance Status  Megestrol/*ANALOGS &
       DERIVATIVES/ADMINISTRATION & DOSAGE/  THERAPEUTIC USE  Middle Age
       Psychometrics  *Quality of Life  Questionnaires  CLINICAL TRIAL  JOURNAL
       ARTICLE  MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).